Background:Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 IgG1 designed to block CTLA-4 cytotoxic T-lymphocyte associated antigen 4 from interacting with its ligands CD80 and CD86. CTLA-4 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.